Improving the decision to switch from first to second-line therapy in MS: a dynamic scoring system - Archive ouverte HAL
Communication Dans Un Congrès Année : 2021

Improving the decision to switch from first to second-line therapy in MS: a dynamic scoring system

1 SPHERE - MethodS in Patients-centered outcomes and HEalth ResEarch
2 UCBL - Université Claude Bernard Lyon 1
3 CRNL - Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center
4 HCL - Hospices Civils de Lyon
5 OFSEP - Observatoire Français de la Sclérose En Plaques [Lyon]
6 REPERES - Recherche en Pharmaco-épidémiologie et Recours aux Soins
7 EHESP - École des Hautes Études en Santé Publique [EHESP]
8 APEMAC - Adaptation, mesure et évaluation en santé. Approches interdisciplinaires
9 Service de neurologie [CHRU Nancy]
10 Service de Neurologie [Strasbourg]
11 Centre d’Investigation Clinique Plurithématique (CIC - P) - CIC Strasbourg
12 Département Neurologie [CHU Toulouse]
13 CRC-SEP Toulouse - Centre Ressources et Compétences sclérose en plaques (CRC-SEP) [CHU Toulouse]
14 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
15 U1064 Inserm - CRTI - Centre de Recherche en Transplantation et Immunologie
16 U1215 Inserm - UB - Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale
17 CIC Bordeaux
18 TIMONE - Hôpital de la Timone [CHU - APHM]
19 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
20 CRC-SEP Nord-Pas de Calais - Centre de Ressources et de Compétences sur la Sclérose en Plaques (CRC-SEP) [Lille]
21 Université de Lille
22 CIC - Centre d'Investigation Clinique [Rennes]
23 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
24 MICMAC - Microenvironment, Cell Differentiation, Immunology and Cancer
25 Service de Neurologie [CHU Nice]
26 URRIS UR2CA - Unité de Recherche Clinique de la Côte d’Azur
27 Neuro-Dol - Neuro-Dol
28 CHU Clermont-Ferrand
29 IGF - Institut de Génomique Fonctionnelle
30 Pôle NIRR - Service de Neurologie [CHU Nimes]
31 CHU ST-E - Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne]
32 CHU Reims - Hôpital universitaire Robert Debré [Reims]
33 ICM - Institut du Cerveau = Paris Brain Institute
34 CHU Saint-Antoine [AP-HP]
35 CHU Amiens-Picardie
36 CHU de Martinique - Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique]
37 CHU Pitié-Salpêtrière [AP-HP]
38 Service de Neurologie [CHRU Besançon]
39 Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy]
40 Centre Hospitalier de Saint-Denis [Ile-de-France]
41 Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon)
42 Fondation Ophtalmologique Adolphe de Rothschild [Paris]
43 CHU Rouen
44 CHU Henri Mondor [Créteil]
45 CHU Montpellier
46 Hôpital Dupuytren [CHU Limoges]
47 Service de Neurologie [CHU Caen]
48 CHU Trousseau [Tours]
49 CHU de Poitiers [La Milétrie] - Centre hospitalier universitaire de Poitiers = Poitiers University Hospital
50 Service de neurologie [Le Kremlin Bicêtre]
51 Hôpital Sud Francilien Corbeil Essonne
52 CHV - Centre Hospitalier de Versailles André Mignot
53 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
J. Pelletier
Xavier Moisset
A. Al Khedr
  • Fonction : Auteur
Elisabeth Maillart
Bertrand Bourre
Alexis Montcuquet
Gilles Defer
A. Maurousset

Résumé

Introduction: In relapsing-remitting multiple sclerosis (RRMS), the early identification of suboptimal responders would prevent irreversible disability progression. Objectives: We aimed to develop and validate a dynamic scoring system to help in the early decision of switch from first to second-line therapy. Methods: From a French cohort of 12,823 patients with RRMS and by using time-dependent propensity scores, we constructed a 1:1 emulated clinical trial (ECT) to compare patients who switched to a second-line treatment because of inefficacy versus comparable patients remaining on first-line treatment. Then, we proposed a frailty Cox model to predict the time to relapse according to the two groups. The validation of the scoring system was performed by two additional ECTs from independent patients. Results: From the learning ECT, the switch benefit was higher for younger patients at the disease onset, with a low level of EDSS at first-line therapy initiation, or in case of at least one observed relapse or Gd-enhancing T1 lesion. It allowed to predict the individual hazard ratio (iHR) of relapse in case of switch versus waiting and to identify two sub-populations: the patients with iHR⩽0.69 with a significant benefit of the switch and the others. From the validation ECT of 348 independent patients with iHR⩽0.69, we reported the 5-year relapse-free survival at 0.14 (95%CI from 0.09 to 0.22) in the waiting group and 0.40 (95%CI from 0.32 to 0.51) in the switched group. From the validation ECT of 518 independent patients iHR>0.69, these values equalled 0.37 (95%CI from 0.30 to 0.46) and 0.44 (95%CI from 0.37 to 0.52), respectively. Conclusions: Based on an original methodology for causal prediction, we proposed a dynamic scoring system to support the early decision to switch to second-line therapy. We estimated that at least one-third of patients could benefit from an earlier switch to prevent relapses.

Dates et versions

hal-03464227 , version 1 (03-12-2021)

Identifiants

Citer

C. Sabathe, Romain Casey, S. Vukusic, Emmanuelle Leray, G. Mathey, et al.. Improving the decision to switch from first to second-line therapy in MS: a dynamic scoring system. 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2021), European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct 2021, Virtuel - Online, France. pp.22-24, Oral Presentation 035, ⟨10.1177/13524585211044647⟩. ⟨hal-03464227⟩
167 Consultations
0 Téléchargements

Altmetric

Partager

More